Erbi Biosystems is revolutionizing cell therapy and bioprocessing process development with the Breez, a fully automated 2 mL TruePerfusion™ bioreactor. Scarce and expensive raw materials no longer restrict generation of process development data enabling improved CMC. A single 2mL volume cassette can deliver up to 400M (CHO and T-cells), sufficient for most development needs and a number of CAR-T clinical dose regimes.
The platform offers a 90% footprint reduction using disposable, functionally closed single-use cassettes with proprietary microfluidic technology processes capable of performing activation, transduction, intensified growth, and diafiltration steps. It offers closed-loop control of pH, total cell density (OD), dissolved oxygen, and CO2 measurements. The integrated online sensors and intuitive software deliver sophisticated feeding strategies, increased cell concentration, low shear, bubble-free mixing with high kLa resulting in performance far exceeding the static and benchtop reactors typically used today.
#CellTherapy4All #CellTherapyforAll
The platform offers a 90% footprint reduction using disposable, functionally closed single-use cassettes with proprietary microfluidic technology processes capable of performing activation, transduction, intensified growth, and diafiltration steps. It offers closed-loop control of pH, total cell density (OD), dissolved oxygen, and CO2 measurements. The integrated online sensors and intuitive software deliver sophisticated feeding strategies, increased cell concentration, low shear, bubble-free mixing with high kLa resulting in performance far exceeding the static and benchtop reactors typically used today.
#CellTherapy4All #CellTherapyforAll
Employees: 11-50
Total raised: $3.8M
Founded date: 2006
Investors 1
| Date | Name | Website |
| 29.01.2023 | Bantam Gro... | bantamgrou... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.11.2020 | - | $3.8M | - |
Mentions in press and media 5
| Date | Title | Description |
| 04.01.2022 | Erbi Biosystems Raises $4M to Provide Small-Scale Perfusion Bioreactors for Development and Manufacture of Cell Therapies | CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Erbi Biosystems, developer of innovative, small-scale, automated, and high-performance cell culture systems, has closed a private round of funding totaling $4M. This latest financing will enabl... |
| 02.11.2020 | Erbi Biosystems Raises $3.8M in Funding | Erbi Biosystems, a Woburn, MA-based microfluidic bioprocess instrumentation company based on technology developed at MIT, closed a $3.8M funding round. The round was led by Jaguar Biotech. The company intends to use the funds to expand manu... |
| 30.10.2020 | Erbi Biosystems Closes $3.8 Million Financing | Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings the total investment received to nearly $4M. The round was l... |
| 30.10.2020 | Erbi Biosystems Closes $3.8 Million Financing | Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings the total investment received to nearly $4M. The round was l... |
| - | Erbi Biosystems Raises $4 Million In Funding | Erbi Biosystems recently announced it raised $4 million in funding. These are the details. Erbi Biosystems – the developer of innovative, small-scale, automated, and high-performance cell culture systems – recently announced it raised $4 mi... |